针对1型糖尿病的疾病修饰疗法:专注于Teplizumab
Chantal Mathieu1, Emily K Sims2, Lucienne Chatenoud3
1Department of Endocrinology, KU Leuven, Leuven, Belgium.
Diabetes care
|November 6, 2025
概括
作为1型糖尿病的新疗法,Teplizumab可将疾病的进展延迟近三年. 这种免疫疗法通过向自身免疫反应,为管理1型糖尿病提供了一种新的方法.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 临床医学 临床医学
背景情况:
- 全球1型糖尿病发病率正在上升.
- 目前的治疗重点是症状管理 (胰岛素).
- 疾病修饰疗法正在出现.
研究的目的:
- 审查teplizumab的作用机制.
- 讨论它在临床实践中的作用.
- 突出其作为疾病修饰疗法的潜力.
主要方法:
- 利祖马布是一种单克隆抗体,向T淋巴细胞上的CD3.
- 它调节T细胞反应,包括耗尽和调节性T细胞诱导.
- 该机制涉及通过CD3/TCR进行部分激进信号传递.
主要成果:
- 德普利祖马布可将2期至3期1型糖尿病的进展延迟约3年.
- 它通过影响T淋巴细胞群体恢复自我耐受性.
- 通过影响T淋巴细胞群体恢复自我耐受性.
结论:
- 德普利祖马布代表了1型糖尿病治疗的重大进展.
- 疾病修饰正在成为护理的新标准.
- 通过查进行早期干预可以进行预防性治疗.
相关概念视频
Diabetes: Management and Pharmacotherapy
835
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
835
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
435
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
435
Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163


